Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial

Authors: Cinat, Gabriela, Fein, Luis Enrique, Brown, Michael, Guminski, Alexander, Haydon, Andrew, Khattak, Adnan, McNeil, Catriona, Parente, Phillip, Power, Jeremy, Roberts-Thomson, Rachel, Sandhu, Shahneen, Underhill, Craig, Varma, Suresh, Berger, Thomas, Awada, Ahmad, Blockx, Nathalie, Buyse, Veronique, Mebis, Jeroen, Franke, Fábio André, Jobim de Azevedo, Sérgio, Silva Lazaretti, Nicolas, Jamal, Rahima, Mihalcioiu, Catalin, Petrella, Teresa, Savage, Kerry, Song, Xinni, Wong, Ralph, Dabelic, Nina, Plestina, Stjepko, Vojnovic, Zeljko, Arenberger, Petr, Kocak, Ivo, Krajsova, Ivana, Kubala, Eugen, Melichar, Bohuslav, Vantuchova, Yvetta, Putnik, Kadri, Dreno, Brigitte, Dutriaux, Caroline, Grob, Jean-Jacques, Joly, Pascal, Lacour, Jean-Philippe, Meyer, Nicolas, Mortier, Laurent, Thomas, Luc, Fluck, Michael, Gambichler, Thilo, Hassel, Jessica, Hauschild, Axel, Schadendorf, Dirk, Donnellan, Paul, McCaffrey, John, Power, Derek, Ariad, Samuel, Bar-Sela, Gil, Hendler, Daniel, Ron, Ilan, Schachter, Jacob, Ascierto, Paolo, Berruti, Alfredo, Bianchi, Luca, Chiarion Sileni, Vanna, Cognetti, Francesco, Danielli, Riccardo, Di Giacomo, Anna Maria, Gianni, Luca, Goldhirsch, Aron, Guida, Michele, Maio, Michele, Mandalà, Mario, Marchetti, Paolo, Queirolo, Paola, Santoro, Armando, Kapiteijn, Ellen, Mackiewicz, Andrzej, Rutkowski, Piotr, Ferreira, Paula, Demidov, Lev, Gafton, Georgy, Makarova, Yulia, Andric, Zoran, Babovic, Nada, Jovanovic, Darjana, Kandolf Sekulovic, Lidija, Cohen, Graham, Dreosti, Lydia, Vorobiof, Daniel, Curiel Garcia, Maria Teresa, Diaz Beveridge, Roberto, Majem Tarruella, Margarita, Marquez Rodas, Ivan, Puliats Rodriguez, Jose-M, Rueda Dominguez, Antonio, Maroti, Marianne, Papworth, Karin, Michielin, Olivier, Bondarenko, Igor, Brown, Ewan, Corrie, Pippa, Harries, Mark, Herbert, Christopher, Kumar, Satish, Martin-Clavijo, Agustin, Middleton, Mark, Patel, Poulam, Talbot, Toby, Agarwala, Sanjiv, Chapman, Paul, Conry, Robert, Doolittle, Gary, Gangadhar, Tara, Hallmeyer, Sigrun, Hamid, Omid, Hernandez-Aya, Leonel, Johnson, Douglas, Kass, Frederic, Kolevska, Tatjana, Lewis, Karl, Lunin, Scott, Salama, April, Sikic, Branimir, Somer, Bradley, Spigel, David, Whitman, Eric, Ascierto, Paolo A, Goodman, Grant R, Simmons, Brian, Ye, Chenglin, Yan, Yibing

Source: In The Lancet Oncology April 2018 19(4):510-520

Real-World Effectiveness, Safety, and Health-Related Quality of Life in Patients Receiving Adjuvant Nivolumab for Melanoma in Belgium and Luxembourg: Results of PRESERV MEL †.

Authors: Rogiers, Anne, Willemot, Laurence, McDonald, Laura, Van Campenhout, Hilde, Berchem, Guy, Jacobs, Celine, Blockx, Nathalie, Rorive, Andrée, Neyns, Bart

Source: Cancers; Oct2023, Vol. 15 Issue 19, p4823, 20p

Subject Terms: SCIENTIFIC observation, CONFIDENCE intervals, MELANOMA, MILD cognitive impairment, RETROSPECTIVE studies, ACQUISITION of data, TREATMENT effectiveness, COMPARATIVE studies, DISEASE relapse, NIVOLUMAB, QUALITY of life, MEDICAL records, QUESTIONNAIRES, RESEARCH funding, PROGRESSION-free survival, PATIENT safety, LONGITUDINAL method, EVALUATION

Geographic Terms: BELGIUM, LUXEMBOURG